AGIO Valuation

Agios Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

37.780

-2.22(-5.550%)1D

Overview
Forecast
Valuation
Earnings

AGIO Relative Valuation

AGIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AGIO is overvalued; if below, it's undervalued.

Historical Valuation

Agios Pharmaceuticals Inc (AGIO) is now in the Fair zone, suggesting that its current forward PS ratio of 49.84 is considered Fairly compared with the five-year average of -2.52. The fair price of Agios Pharmaceuticals Inc (AGIO) is between 28.06 to 45.49 according to relative valuation methord.

Relative Value

Fair Zone

28.06-45.49

Current Price：39.72

Fair

-5.28

Trailing

Forward

-1.97

EV/EBITDA

Agios Pharmaceuticals Inc. (AGIO) has a current EV/EBITDA of -1.97. The 5-year average EV/EBITDA is -2.95. The thresholds are as follows: Strongly Undervalued below -8.43, Undervalued between -8.43 and -5.69, Fairly Valued between -0.21 and -5.69, Overvalued between -0.21 and 2.54, and Strongly Overvalued above 2.54. The current Forward EV/EBITDA of -1.97 falls within the Historic Trend Line -Fairly Valued range.

-1.90

EV/EBIT

Agios Pharmaceuticals Inc. (AGIO) has a current EV/EBIT of -1.90. The 5-year average EV/EBIT is -2.76. The thresholds are as follows: Strongly Undervalued below -7.55, Undervalued between -7.55 and -5.15, Fairly Valued between -0.36 and -5.15, Overvalued between -0.36 and 2.03, and Strongly Overvalued above 2.03. The current Forward EV/EBIT of -1.90 falls within the Historic Trend Line -Fairly Valued range.

49.84

Agios Pharmaceuticals Inc. (AGIO) has a current PS of 49.84. The 5-year average PS is 373.86. The thresholds are as follows: Strongly Undervalued below -2212.20, Undervalued between -2212.20 and -919.17, Fairly Valued between 1666.89 and -919.17, Overvalued between 1666.89 and 2959.92, and Strongly Overvalued above 2959.92. The current Forward PS of 49.84 falls within the Historic Trend Line -Fairly Valued range.

-7.65

P/OCF

Agios Pharmaceuticals Inc. (AGIO) has a current P/OCF of -7.65. The 5-year average P/OCF is -5.17. The thresholds are as follows: Strongly Undervalued below -14.39, Undervalued between -14.39 and -9.78, Fairly Valued between -0.56 and -9.78, Overvalued between -0.56 and 4.05, and Strongly Overvalued above 4.05. The current Forward P/OCF of -7.65 falls within the Historic Trend Line -Fairly Valued range.

-6.39

P/FCF

Agios Pharmaceuticals Inc. (AGIO) has a current P/FCF of -6.39. The 5-year average P/FCF is -5.96. The thresholds are as follows: Strongly Undervalued below -19.42, Undervalued between -19.42 and -12.69, Fairly Valued between 0.77 and -12.69, Overvalued between 0.77 and 7.50, and Strongly Overvalued above 7.50. The current Forward P/FCF of -6.39 falls within the Historic Trend Line -Fairly Valued range.

Agios Pharmaceuticals Inc (AGIO) has a current Price-to-Book (P/B) ratio of 1.58. Compared to its 3-year average P/B ratio of 1.81 , the current P/B ratio is approximately -12.70% higher. Relative to its 5-year average P/B ratio of 2.35, the current P/B ratio is about -32.87% higher. Agios Pharmaceuticals Inc (AGIO) has a Forward Free Cash Flow (FCF) yield of approximately -17.58%. Compared to its 3-year average FCF yield of -19.35%, the current FCF yield is approximately -9.14% lower. Relative to its 5-year average FCF yield of -18.33% , the current FCF yield is about -4.06% lower.

1.58

P/B

Median3y

1.81

Median5y

2.35

-17.58

FCF Yield

Median3y

-19.35

Median5y

-18.33

Competitors Valuation Multiple

The average P/S ratio for AGIO's competitors is 29.28, providing a benchmark for relative valuation. Agios Pharmaceuticals Inc Corp (AGIO) exhibits a P/S ratio of 49.84, which is 70.25% above the industry average. Given its robust revenue growth of 6.56%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AGIO.O

Agios Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Loss

2.33B

APLS.O

Apellis Pharmaceuticals Inc

Harmony Biosciences Holdings Inc

IDEAYA Biosciences Inc

Performance Decomposition

Market capitalization of AGIO decreased by 13.79% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 8.19M to 8.73M.

The secondary factor is the Margin Expansion, contributed 2.75%to the performance.

Overall, the performance of AGIO in the past 1 year is driven by Revenue Growth. Which is more sustainable.

6.56%

8.19M → 8.73M

Revenue Growth

2.75%

-995.84 → -1.02K

Margin Expansion

-23.10%

4.54 → 3.49

P/E Change

-13.79%